ethics
Bootstrap Bio and Manhattan Genomics, biotech firms launched last year to pursue human embryo editing for preventing serious diseases, have closed their doors. The companies cited financial difficulties and internal conflicts as reasons for the shutdowns. The developments highlight challenges in the controversial field of gene-edited babies.
Riportato dall'IA
A billionaire-backed biotech startup, R3 Bio, is developing genetically engineered 'organ sacks'—whole organ systems without a brain—as an alternative to animal testing. This idea comes as the Trump administration phases out animal experimentation across the federal government. A cofounder states the long-term goal is to create human versions.